• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Andaris files ultrasound contrast IND

Article

Ultrasound contrast developer Andaris of Nottingham, UK, has filed an investigational new drug (IND) application with the Food and Drug Administration to begin phase II clinical trials for cardiac indications of its Quantison agent. The application

Ultrasound contrast developer Andaris of Nottingham, UK, has filed an investigational new drug (IND) application with the Food and Drug Administration to begin phase II clinical trials for cardiac indications of its Quantison agent. The application covers the use of Quantison for left ventricular opacification as well as myocardial perfusion indications. Quantison consists of air-filled albumin microcapsules developed for intravenous imaging (SCAN 2/5/97).

Recent Videos
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Related Content
© 2025 MJH Life Sciences

All rights reserved.